New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
08:26 EDTICPT, GEVALeerink reiterates caution on Intercept ahead of FLINT data
Leerink says the physicians it spoke to at its Healthcare Insights Conference who treat liver diseases were cautious on Intercept's (ICPT) obeticholic acid's clinical potential in non-alcoholic steatohepatitis due to its effect on LDL-C. Leerink remains cautious on the stock ahead of full FLINT data in the second half of 2014, as it believes there is as much if not more downside than upside due to safety concerns. The firm adds the specialists noted that they have screened and not found any patients that warrant treatment with an expensive enzyme replacement therapy, such as Synageva's (GEVA) sebelipase alfa.
News For ICPT;GEVA From The Last 14 Days
Check below for free stories on ICPT;GEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 28, 2014
17:05 EDTICPTOrbiMed reports 7% stake in Intercept
Subscribe for More Information
August 26, 2014
07:46 EDTICPTIntercept Pharmaceuticals volatility at low end of historic range
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use